论文部分内容阅读
目的 研究甲磺酸左氧氟沙星口服给药后在肺结核患者体内的药代动力学特性。方法 采用高效液相色谱法测定血清中甲磺酸左氧氟沙星浓度 ,以 3P97药代动力学程序计算药代动力学参数。结果 8例肺结核患者po 40 0mg甲磺酸左氧氟沙星后 ,体内过程符合一室开放模型。tmax为 1.2 2h ,cmax为 (4.5 2± 0 .72 )mg·L-1,一次给药 2 4h后血药浓度为 (0 .5 2± 0 .2 6 )mg·L-1,AUC为 (48.35± 5 .38)mg·h·L-1,t1/ 2 为 (6 .49± 1.70 )h ,V/F(c)为 (77.48± 8.33)L。结论 肺结核患者服用甲磺酸左氧氟沙星 ,推荐每次 40 0mg ,每日二次的服药方法。对肝肾功能不全的患者 ,防止出现不良反应。
Objective To study the pharmacokinetics of levofloxacin mesylate in patients with pulmonary tuberculosis after oral administration. Methods The concentration of levofloxacin mesylate in serum was determined by HPLC and the pharmacokinetic parameters were calculated by 3P97 pharmacokinetic program. Results Eight patients with pulmonary tuberculosis po 40 0mg levofloxacin mesylate, in vivo process in line with the open chamber model. tmax was 1.2 2 h, cmax was (4.5 2 ± 0.72) mg · L-1, and the plasma concentration was (0. 52 ± 0.2 6) mg · L-1 after 24 hours of primary administration. The AUC was (48.35 ± 5.38) mg · h · L-1, t1 / 2 was (6.49 ± 1.70) h and V / F (c) was (77.48 ± 8.33) L. Conclusion Pulmonary tuberculosis patients taking levofloxacin mesylate, 40 mg each time, twice daily medication. In patients with liver and kidney dysfunction, to prevent adverse reactions.